EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

177Lu-Labeled Iron Oxide Nanoparticles Functionalized with Doxorubicin and Bevacizumab as Nanobrachytherapy Agents against Breast Cancer

Evangelia-Alexandra Salvanou iD, Argiris Kolokithas-Ntoukas iD, Danai Prokopiou iD, Maria Theodosiou iD, Eleni Efthimiadou iD, Przemysław Koźmiński iD, Stavros Xanthopoulos iD, Konstantinos Avgoustakis iD, Penelope Bouziotis iD

Molecules · 2024

DOI: 10.3390/molecules29051030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Evangelia-Alexandra Salvanou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research "Demokritos", 15341 Athens, Greec…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Nanoparticles, Breast Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: State Scholarship Foundation IKY, State Scholarships Foundation (IKY).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The use of conventional methods for the treatment of cancer, such as chemotherapy or radiotherapy, and approaches such as brachytherapy in conjunction with the unique properties of nanoparticles could enable the development of novel theranostic agents. The aim of our current study was to evaluate the potential of iron oxide nanoparticles, coated with alginic acid and polyethylene glycol, functionalized with the chemotherapeutic agent doxorubicin and the monoclonal antibody bevacizumab, to serve as a nanoradiopharmaceutical agent against breast cancer. Direct radiolabeling with the therapeutic isotope Lutetium-177 (177Lu) resulted in an additional therapeutic effect. Functionalization was accomplished at high percentages and radiolabeling was robust. The high cytotoxic effect of our radiolabeled and non-radiolabeled nanostructures was proven in vitro against five different breast cancer cell lines. The ex vivo biodistribution in tumor-bearing mice was investigated with three different ways of administration. The intratumoral administration of our functionalized radionanoconjugates showed high tumor accumulation and retention at the tumor site. Finally, our therapeutic efficacy study performed over a 50-day period against an aggressive triple-negative breast cancer cell line (4T1) demonstrated enhanced tumor growth retention, thus identifying the developed nanoparticles as a promising nanobrachytherapy agent against breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsNanoparticlesBreast NeoplasmsHumansAnimalsMiceFemaleBevacizumabTissue DistributionDoxorubicinMagnetic Iron Oxide NanoparticlesCell Line, Tumor

Stichwörter der Autor:innen

Lutetium-177MTTbevacizumabbiodistributionbreast cancerdoxorubiciniron oxide nanoparticlesnanobrachytherapyradiolabelingtherapeutic efficacy

Substanzen

BevacizumabDoxorubicin

Autor:innen und Institutionen

  • Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research "Demokritos", 15341 Athens, Greece.
  • Department of Pharmacy, School of Health Sciences, University of Patras, 26504 Patras, Greece.
  • Laboratory of Inorganic Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou, 15771 Athens, Greece.
  • Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16 Str., 03-195 Warsaw, Poland.

ORCID-Profile: Evangelia-Alexandra Salvanou, Argiris Kolokithas-Ntoukas, Danai Prokopiou, Maria Theodosiou, Eleni Efthimiadou, Przemysław Koźmiński, Stavros Xanthopoulos, Konstantinos Avgoustakis, Penelope Bouziotis

Förderung

  • State Scholarship Foundation IKY
  • State Scholarships Foundation (IKY)

Zitieren

APA

Salvanou, E. A., Kolokithas-Ntoukas, A., Prokopiou, D., Theodosiou, M., Efthimiadou, E., Koźmiński, P., Xanthopoulos, S., Avgoustakis, K., & Bouziotis, P. (2024). 177Lu-Labeled Iron Oxide Nanoparticles Functionalized with Doxorubicin and Bevacizumab as Nanobrachytherapy Agents against Breast Cancer. Molecules. https://doi.org/10.3390/molecules29051030

Vancouver

Salvanou EA, Kolokithas-Ntoukas A, Prokopiou D, Theodosiou M, Efthimiadou E, Koźmiński P, et al. 177Lu-Labeled Iron Oxide Nanoparticles Functionalized with Doxorubicin and Bevacizumab as Nanobrachytherapy Agents against Breast Cancer. Molecules. 2024. doi:10.3390/molecules29051030

BibTeX
@article{Salvanou2024,
  author = {Salvanou, Evangelia-Alexandra and Kolokithas-Ntoukas, Argiris and Prokopiou, Danai and Theodosiou, Maria and Efthimiadou, Eleni and Koźmiński, Przemysław and Xanthopoulos, Stavros and Avgoustakis, Konstantinos and Bouziotis, Penelope},
  title = {177Lu-Labeled Iron Oxide Nanoparticles Functionalized with Doxorubicin and Bevacizumab as Nanobrachytherapy Agents against Breast Cancer},
  journal = {Molecules},
  year = {2024},
  doi = {10.3390/molecules29051030}
}
Kostenlos starten →